The expansion in gross margin, alongside a doubling of operating margin to 1.1%, suggests that cost discipline and favorable product mix are providing modest relief in an inherently constrained profitability profile. However, the minimal buffer of approximately 300 basis points between gross and operating margins indicates that any adverse shift in regulatory policies, generic pricing, or logistics costs could rapidly erode earnings power.

The volatility in ROIC appears driven more by changes in inventory and receivables management than by sustainable improvements in core operational returns, as evidenced by the inconsistent correlation with net margin trends. Investors should monitor for stabilization above the 20% level as a potential indicator of compounding capability, but the erratic pattern suggests that integration of acquired assets remains a headwind to predictable capital deployment.

The negative equity base renders traditional leverage ratios meaningless, shifting focus to D/EBITDA and interest coverage, which have normalized from extreme levels but still indicate substantial debt reliance. The company's ability to service debt appears stable based on current EBITDA generation, yet the high absolute debt load increases vulnerability to operational downturns or credit market tightening, particularly as acquisitions have fueled balance sheet expansion.

This liquidity structure, characterized by a quick ratio below 0.5 and a negative cash conversion cycle, indicates that Cardinal Health effectively uses supplier credit to fund operations, a common distribution model that enhances cash efficiency but heightens dependence on the creditworthiness of its vendor base. Any disruption in payment terms or unexpected inventory demands could strain this model, as evidenced by historical working capital swings that have periodically overwhelmed operating cash flow.